logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pembrolizumab in combination with olaparib for anti-hormone and chemotherapy failure metastatic castration-resistant prostate cancer – third line

< Back

Pembrolizumab in combination with olaparib for anti-hormone and chemotherapy failure metastatic castration-resistant prostate cancer – third line

Drugs

Cancer and Palliative Care

May 2020


Pembrolizumab in combination with olaparib is in clinical development for patients with metastatic and castration-resistant prostate cancer. Prostate cancer is a cancer of the prostate gland (a small organ in a man’s pelvis) and is the most common cancer in men in the UK. Prostate cancer can be localised, locally advanced or advanced (metastatic). The symptoms of prostate cancer may vary depending on the stage but can include pain, tiredness, and problems emptying the bladder and the bowels.

Pembrolizumab delivered via intravenous infusion is a type of immunotherapy. It stimulates the body’s immune system to fight cancer cells by targeting specific proteins that stimulate an immune response. Olaparib is administered orally in tablet form and can lead to cancer cell death by blocking DNA repair by an enzyme (protein) called PARP. If licensed, pembrolizumab in combination with olaparib will provide a therapy option for a heavily pre-treated patient population with limited remaining treatments available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts